NeuroDerm (NDRM) Misses Q3 EPS by 15c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/10/2026
Go back to NeuroDerm (NDRM) Misses Q3 EPS by 15c
November 11, 2015 9:28 AM EST
Raymond James initiated coverage on Neuroderm Ltd (NASDAQ: NDRM) with an Outperform rating and a price target of $28.00.
For an analyst ratings summary and ratings history on Neuroderm Ltd click here. For more ratings news on Neuroderm Ltd click here.
Shares of Neuroderm Ltd closed at $18.86 yesterday.
...
More
November 11, 2015 7:01 AM EST
NeuroDerm (Nasdaq: NDRM) announced that it has modified its U.S. development plan for ND0612H and ND0612L, the company's continuous, subcutaneously delivered levodopa/carbidopa product candidates for the treatment of Parkinson's disease. The updated and abbreviated plan incorporates written feedback that the company recently received from the U.S. Food and Drug Administration (FDA) within the framework of an ongoing Type C meeting communication that was initiated by the company. NeuroDerm asked the agency to provide strategic and operational guidance related to the U.S. clinical and regulatory development of... More
